Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

ViGeneron and Daiichi Sankyo collaborate to evaluate vgAAV for novel ophthalmic gene therapy

Jan. 18, 2021

Interim analysis data from phase IIb study of iDose TR sustained-release travoprost implant

Jan. 14, 2021

Phase III RESCUE study of rAAV2/2-ND4 does not meet primary endpoint

Jan. 14, 2021

Rezolute initiates first-in-human study of RZ-402

Jan. 13, 2021

European Commission approves Roclanda ophthalmic solution

Jan. 12, 2021

AMMS synthesizes new adenosine A2A receptor agonists

Jan. 11, 2021

Aldeyra reports topline phase III data on reproxalap in dry eye disease

Jan. 8, 2021

REGENXBIO announces development updates for RGX-314 and RGX-202

Jan. 8, 2021

Treatment begins in phase I/IIa trial of AXT-107 in DME

Jan. 7, 2021

Redwood reports further phase II data analysis on RP-101 for dry eye

Dec. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...